Unity Biotechnology Inc [NASDAQ: UBX] plunged by -$0.48 during the normal trading session on while it closed the day at $1.33.
Unity Biotechnology Inc stock has also gained 36.21% of its value over the past 7 days. However, UBX stock has declined by -10.74% in the 3 months of the year. Over the past six months meanwhile, it has lost -8.28% and gained 36.21% year-on date.
The market cap for UBX stock reached $22.41 million, with 16.85 million shares outstanding and 15.37 million shares in the current float. Compared to the average trading volume of 116.14K shares, UBX reached a trading volume of 457248 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Unity Biotechnology Inc [UBX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for UBX shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on UBX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Rodman & Renshaw have made an estimate for Unity Biotechnology Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 22, 2024. While these analysts kept the previous recommendation, Wedbush raised their target price from $2 to $4. The new note on the price target was released on November 16, 2023, representing the official price target for Unity Biotechnology Inc stock. On November 10, 2021, analysts increased their price target for UBX shares from 5 to 7.
The Average True Range (ATR) for Unity Biotechnology Inc is set at 0.16 The Price to Book ratio for the last quarter was 1.58, with the Price to Cash per share for the same quarter was set at 1.72.
UBX stock trade performance evaluation
Unity Biotechnology Inc [UBX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 36.21. With this latest performance, UBX shares gained by 11.76% in over the last four-week period, additionally sinking by -8.28% over the last 6 months – not to mention a drop of -30.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for UBX stock in for the last two-week period is set at 54.48, with the RSI for the last a single of trading hit 54.03, and the three-weeks RSI is set at 53.79 for Unity Biotechnology Inc [UBX]. The present Moving Average for the last 50 days of trading for this stock 1.1956, while it was recorded at 1.4680 for the last single week of trading, and 1.4148 for the last 200 days.
Unity Biotechnology Inc [UBX]: An insightful look at the core fundamentals
Unity Biotechnology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.45 and a Current Ratio set at 3.45.
Unity Biotechnology Inc [UBX]: Institutional Ownership
There are presently around $20.55%, or 20.82%% of UBX stock, in the hands of institutional investors.
